Business Wire

Axelera Announces Europa AIPU, Setting New Industry Benchmark for AI Accelerator Performance, Power Efficiency and Affordability

21.10.2025 15:00:00 EEST | Business Wire | Press release

Share

Axelera AI, the leading provider of purpose-built AI hardware acceleration technology, today announced Europa™, an AI processor unit (AIPU) that sets a new performance/price standard for multi-user generative AI and computer vision applications. Europa’s combination of processing power, energy and thermal efficiency, compact packaging, and multiple form factor options make it ideal for compute-intensive, multi-modal AI inference applications from the edge to enterprise servers. Designed to be cost effective and accessible, Europa enables any organization to unlock the power of cutting-edge AI applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021493990/en/

Europa™ AIPU

Next Gen Architecture for Real World AI Processing Power

The Europa AIPU features eight second-generation AI cores, each incorporating Axelera’s advanced Digital In-Memory Compute (D‑IMC) technology and large vector engines, delivering up to 629 TOPS at INT8 precision. Complementing the AI cores are two clusters of eight dedicated RISC‑V vector processing cores for non-AI pre- and post-processing, achieving a peak performance of 4915 GOPS. An integrated H.264/H.265 decoder further offloads media tasks, enabling customers to reserve the host CPU entirely for business logic and application-level workloads. These cores, programmable through the Voyager SDK, will provide better total cost of ownership than having to offload to other hardware.

Europa’s purpose-built architecture eliminates memory bottlenecks by integrating 128MB of on-chip L2 SRAM and 256-bit LPDDR5 interface to provide 200GB/s bandwidth. This high throughput design delivers 3 to 5 times performance efficiency (performance per watt and performance per dollar) over the leading industry solutions in the same product category, as well as delivering best-in-class performance for generative AI solutions.

“Organizations shouldn't have to choose between the raw compute power they want and the real-world usability they need,” said Fabrizio del Maffeo, CEO of Axelera. “Europa makes enterprise class AI processing power available to nearly anyone. From manufacturing automation to intelligent surveillance to autonomous systems, Europa enables the next generation of breakthrough AI applications without compromise, complexity or massive budgets. We’re changing the equation of what’s possible with AI at scale.”

With its Europa and Metis AIPU platforms, Axelera offers a full range of accessible AI accelerator solutions for everything from very low-power, size-constrained edge device applications to more demanding and performance-intensive use cases including humanoid robotics and enterprise server solutions. Across its product lines, Axelera’s emphasis on optimizing processing power and energy efficiency delivers maximum TOPs for any use case.

Built for Ease of Integration and Deployment

Axelera optimized Europa to simplify design integration and support deployment flexibility. Specifically:

  • Europa’s unified architecture simplifies board design by combining specialized AI cores with 16 RISC-V vector processors and a hardware-accelerated HEVC265 decoder to reduce CPU overhead and enable simultaneous real-time processing of visual, language, sensor, and speech workloads with no external requirements.
  • With multiple form factors and PCIe 4x Gen4 connectivity, Europa seamlessly integrates with a wide variety of hosts making it easy to upgrade existing edge machines and servers with groundbreaking AI capabilities.
  • Europa’s built-in secure enclave technology provides enterprise-grade protection for sensitive workloads.
  • Programmable with the same user-friendly Voyager SDK as Metis, developers can easily leverage the same tool to deliver their inference solutions across a wide range of devices and use cases.
  • Its compact 35x35mm package maximizes performance density, making it ideal for edge deployments while delivering the processing power to meet server and data center needs.

Powerful Local Processing with Europa PCIe

Axelera will also offer the Europa AIPU integrated in a PCIe card form factor. Europa PCIe cards support scalable configurations – from single-chip 16GB to four-chip 256GB solutions – to meet a wide variety of workload requirements. Leveraging the power of Europa, the cards can process complex workloads locally, and preprocess and decode multiple 4K HEVC265 video streams simultaneously, all with minimal latency and economical power consumption.

Shipments for the Europa AIPU and PCIe card will begin in the first half of 2026.

Supporting quotes:

“IT4LIA’s AI Factory initiative is a strategic cornerstone in building a sovereign European infrastructure for artificial intelligence,” said Daniele Cesarini, Head of AI/HPC Architecture at Cineca. “Our collaboration with Axelera AI within the DARE project reflects our commitment to integrating advanced European technologies into national HPC environments. We are ready to host and validate Axelera’s Europa accelerators within our infrastructure, supporting their deployment in real-world, high-performance AI workloads. This partnership is a concrete step toward a scalable, energy-efficient AI ecosystem, and demonstrates how European innovation in semiconductor design can be effectively translated into operational excellence. By working together, we aim to accelerate the adoption of sovereign AI technologies and reinforce Europe’s leadership in sustainable, high-performance computing.”

“At SURF, we empower researchers with world-class digital services and drive innovation through collaboration,” said Valeriu Codreanu, Head of High-Performance Computing and Visualization at SURF. “Our partnership with Axelera AI, using Metis in SURF’s Experimental Technologies Platform and exploring Europa, reflects our excitement for emerging AI technologies that have the potential to transform research.”

"The Ultralytics YOLO family of models has set the industry standard for computer vision globally,” said Glenn Jocher, CEO of Ultralytics. “The performance we've achieved running YOLO models on Axelera AI's Metis platform has been remarkable, delivering the speed and efficiency our users demand for real-world computer vision applications. Our collaboration has proven that advanced AI inference can be both powerful and accessible. With Europa's expanded capabilities coming next year, we're excited to broaden YOLO's deployment across entirely new use cases.”

“As a company at the forefront of AI innovation, Almawave is excited to collaborate with Axelera AI on the launch of Europa,” said Valeria Sandei, CEO, Almawave S.p.A. “By combining Axelera’s next-generation inference platform with our expertise in developing cutting-edge AI applications and our proprietary language model Velvet, we can deliver powerful, accessible, and energy-efficient solutions to our customers. This partnership reinforces our shared commitment to bringing advanced AI to the Edge, with real impact across industries.”

“SECO is a leading provider of Edge AI solutions, empowering customers to bring intelligence and efficiency directly to their devices,” said Maurizio Caporali, Chief Product Officer at SECO. “We integrated Metis into our Edge AI product line earlier this year and have been impressed by the significant boost in performance and scalability it delivers. We are excited to partner with Axelera as they continue to expand their world-class inference portfolio and enable even broader adoption of AI at the edge across industries.”

“As the leading provider of AI software, Multiverse prides itself on partnering with the very best technology companies to enable our solutions,” said Rodrigo Hernandez, Global Director of Gen AI at Multiverse Computing. “Axelera AI is building world-class hardware that powers the most performant and energy efficient AI inference solutions around the globe. Their next generation of hardware, Europa, will be a welcome addition to our infrastructure as we pursue our mission to make AI faster, cheaper and more energy efficient.”

“E4 Computer Engineering is widely renowned as a leader in integrating the latest technology solutions,” said Cosimo D. Gianfreda, CEO and Co-Founder at E4. “We are testing Metis from Axelera AI and are very impressed with its capabilities as well as the support provided by the Voyager SDK. We firmly believe that their next solution, Europa, offers a leap in performance such that data centers will more efficiently support the needs of their customers and we are prepared to integrate this new solution into our ecosystem.”

About Axelera AI

Axelera AI is the leading provider of purpose-built AI hardware acceleration technology for AI inference, including computer vision and generative AI applications. Its first-generation product is the game-changing Metis™ AI platform – a holistic hardware and software solution for Edge AI inference which delivers the world’s highest performance and power-efficiency at a fraction of the cost of alternative solutions. Headquartered in the AI Innovation Center of the High Tech Campus in Eindhoven, The Netherlands, Axelera AI has R&D offices in Belgium, Switzerland, Italy and the UK, with more than 200 employees in 18 countries. Its team of experts in AI software and hardware hail from top AI firms and Fortune 500 companies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251021493990/en/

Contacts

Media
Axelera@voxuspr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye